Cementing its vision to become the gold standard for EMRs globally, Augnito, an advanced AI-based speech-to-text solution won the best medical product of the year at Asia's Healthcare Excellence Awards 2021 By CMO Asia.

CMO Asia through its objective-oriented methodology helps identify and honor the best in business across various categories. Augnito was chosen as the “Best Innovative Medical Product of the Year”’. Less than 2 years into the launch, Augnito is presently used by 6000+ doctors in 25 states in India and covers more than 50+ medical specialties and subspecialties with ever-increasing clinical lexicon and drug formulary providing the most updated support for doctors.
 

Talking about the win, Rustom Lawyer, Co-founder, Augnito said, “Our mission at Augnito is to Invent the Future of Healthcare keeping Doctors at the heart of everything we do. Couldn't be more proud to have been named the "Best Innovative Medical Product of the Year" at Asia's Healthcare Excellence Awards 2021 by CMO Asia. This award is for the team - We've taken this zero to one journey together and I have full faith that we are doing this with the best team in the business.”

Developed after 7 years of R&D, Augnito was first launched in the Indian market. One year since its launch in India, Augnito has already got traction transforming clinical workflow systems across the healthcare market, landing contracts with leading hospitals and diagnostic centres in the region. Augnito is in association with Japanese company Fujifilm to enable voice recognition within their radiology information system platform and is working with doctors across UAE & South Africa.

About Scribetech

Founded in 2001, Scribetech is a pioneer in the world of healthcare documentation software collaborating with the NHS and independent health sector organisations. The company has now launched Augnito, an AI Medical Voice SaaS technology with the vision to revolutionise and augment digital adoption in the Indian healthcare market.
Advertisements

Post a Comment

Previous Post Next Post
Like this content? Sign up for our daily newsletter to get latest updates.